Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

NCT00651027 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

HEPATITIS C (HCV)

Interventions

DRUG: PF-868554
DRUG: PF-868554
DRUG: PF-868554

Sponsor

Pfizer